

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.

杭州九源基因生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2566)

**INSIDE INFORMATION
ISSUANCE OF FILING NOTICE BY THE CSRC FOR
THE H SHARE FULL CIRCULATION
APPLICATION OF THE COMPANY**

This announcement is made by Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**Inside Information Provisions**”).

Reference is made to the announcement (the “**Announcement**”) of the Company dated December 2, 2025 in relation to the proposed implementation of the H Share Full Circulation by the Company. Unless otherwise stated, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Board is pleased to announce that on April 2, 2026, the CSRC issued a filing notice to the Company (the “**Filing Notice**”) in respect of the H Share Full Circulation. According to the Filing Notice, the filing with the CSRC in relation to the H Share Full Circulation, in respect of the conversion of 136,302,015 Unlisted Shares held by 12 shareholders of the Company into H shares has been completed. If the conversion of the Shares is not completed within 12 months from the date of the Filing Notice, and the Company still intends to proceed, the Company shall update the filing materials with the CSRC. The Company will apply to the Stock Exchange for the listing of, and permission to deal in, such H Shares on the Main Board of the Stock Exchange.

As at the date of this announcement, the details of the implementation plan of the H Share Full Circulation have not been finalized. The Company will make further announcement(s) on the progress of the H Share Full Circulation in compliance with the requirements under the Listing Rules and/or the Inside Information Provisions as and when appropriate.

The H Share Full Circulation is subject to other relevant procedures as required by the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
杭州九源基因生物醫藥股份有限公司
FU Hang
Executive Director, Chairman of the Board and General Manager

Hangzhou, the PRC, April 2, 2026

As at the date of this announcement, the Board comprises (i) Mr. Fu Hang (傅航) and Mr. Zhou Wei (周偉) as executive directors; (ii) Mr. Wu Shihang (吳詩航), Mr. Albert Esteve Cruella, Mr. Fei Junjie (費俊傑) and Ms. Yan Weiting (嚴瑋婷) as non-executive directors; and (iii) Mr. Zhou Zhihui (周智慧), Ms. Ho Mei Yi (何美儀) and Dr. Zhou Demin (周德敏) as independent non-executive directors.